Button Text
About Us
We are committed to developing the transformative biotherapeutics with T cell engaging bispecific antibodies

LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm, in collaboration with Lindis Biotech, is developing Catumaxomab for use in a broad range of cancers globally. Additionally, LintonPharm is developing a next generation bispecific antibody platform to provide a more robust manufacturing and drug design and increased flexibility to individualize the design of each molecule. The current pipeline includes several treatments in development for blood cancer and solid tumors.

We have an industry-leading management team and scientific advisors with rich experience in cancer immunotherapy especially T cell engagers, and with antibody engineering, advancing drug candidates from early-stage research to clinical trials and regulatory approval.

Guided by our core value – science and conscience, we relentlessly build on our expertise in cancer immunology and leading-edge technologies in pursuit of transformative and affordable treatments for cancer patients. We approach each day with our commitment and passion to improve lives of patients, and a sense of humility, recognizing that our strength resides in the diversity of our journeys and the opportunity to learn from each other.

Awards & Milestones
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018-2017

2022.08:2021 China Biotech 50 was authorized by KPMG.
2022.07:2021 Guangzhou Future Star was authorized.
2022.05:Data of Catumaxomab for advanced gastric cancer with peritoneal metastasis was released at 2022 ASCO Annual Meeting.
2022.03:2021 Guangzhou Unicorn Innovative Company was authorized.

2022.01:Enrollment for stage 1 of the global  phase Ⅲ trial of Catumaxomab in patients with advanced gastric cancer has completed.

2021.11:First Patient Dosed in Phase Ⅰ/Ⅱ Clinical Trial of Catumaxomab for Non-Muscle-Invasive Bladder Cancer
2021.06:Potential Unicorn Enterprise was authorized by Huangpu District Guangzhou Development Zone
2021.05:Cohort A Enrollment in Stage 1 of the Global Phase Ⅲ Trial of Catumaxomab for Gastric Cancer completed
2021.03:Sereies B funding Completed
2021.02:PhaseⅠ/Ⅱ Trial of Catumaxomab for Non-Muscle Invasive Bladder Cancer Treatment was authorized by NMPA

2020.11:Pre-IND meeting of LP002 with FDA
2020.10:First Patient Dosed in Stage 1 of the global phase Ⅲ trial of Catumaxomab for Gastric Cancer
2020.07:Phase Ⅲ Trial of Catumaxomab for Gastric Cancer treatment was authorized by NMPA, MFDS and MOHW

2019.08:IND application for Catumaxomab for the treatment of gastric cancer submitted to NMPA.

2018.07:Sereies A funding completed
2017.08:LintonPharm was founded